Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data

Phase 3positivesafusidenibPositive

AI Analysis

Summary

Nuvation Bio will advance safusidenib into Phase III trials for glioma based on positive three-year data, launching both a global pivotal trial and a US Phase II study.

Clinical Trial Data

Phase

Phase III

Primary Endpoint

Met

Outcome Details

positive three-year data

Importance:7/10

Sentiment:

0.80

gliomasafusidenibPhase 3 advancementpositive data

Related Companies

$NUVB-WT

Read the original article

Published by Clinical Trials Arena on July 20, 2026 3:28 PM

Read Original